Is a colonoscopy and esophagogastroduodenoscopy (EGD) required before initiating bevacizumab (Avastin) therapy?

Endoscopic Evaluation Required Before Bevacizumab in Hepatocellular Carcinoma

Yes, patients with hepatocellular carcinoma (HCC) must undergo endoscopic evaluation and treatment for esophageal varices before starting bevacizumab. This is an explicit requirement stated in the 2022 AGA Clinical Practice Guideline for HCC 1.

Mandatory Pre-Treatment Screening for HCC Patients

The AGA guideline specifically states: "Gastrointestinal bleeding is a known adverse effect of bevacizumab and individuals should undergo endoscopic evaluation and treatment for esophageal varices before treatment" 1. This recommendation applies to patients receiving atezolizumab plus bevacizumab as first-line therapy for HCC.

Why This Matters

• Bevacizumab increases bleeding risk through VEGF inhibition, which can destabilize existing varices
• HCC patients frequently have portal hypertension and esophageal varices due to underlying cirrhosis
• Variceal hemorrhage is potentially fatal and represents a preventable complication with proper screening

What the Endoscopy Should Accomplish

The pre-treatment EGD serves two purposes:

1. Identify esophageal varices requiring prophylactic treatment
2. Provide endoscopic intervention (banding or sclerotherapy) for high-risk varices before bevacizumab initiation

Recent data supports this approach: Among HCC patients receiving atezolizumab/bevacizumab, 17% experienced variceal exacerbation and 7.2% had variceal rupture 2. However, when appropriate endoscopic treatment was performed before starting therapy, none of the 28 pre-treated patients developed variceal hemorrhage 3.

Colonoscopy Is NOT Required

Colonoscopy is not mandated before bevacizumab initiation unless there are specific clinical indications unrelated to bevacizumab safety. The guideline and FDA label 4 only specify endoscopic evaluation for esophageal varices (requiring EGD), not lower GI assessment.

Exception for Ovarian Cancer

The FDA label notes to "avoid Avastin in patients with ovarian cancer who have evidence of recto-sigmoid involvement by pelvic examination or bowel involvement on CT scan" 4, but this is assessed by imaging and clinical exam, not routine colonoscopy.

Clinical Implementation Algorithm

For HCC patients being considered for atezolizumab/bevacizumab:

1. Perform EGD within 3 months before treatment initiation 2
2. If varices present (≥F1): Provide endoscopic treatment (banding/sclerotherapy) before starting bevacizumab
3. If no varices or after successful treatment: Proceed with bevacizumab
4. Monitor high-risk patients with:
   • Prior variceal treatment history
   • Drug-resistant ascites
   • Esophageal intramural vessel diameter >3.3 mm on CT
   • Left gastric vein diameter >4.9 mm on CT 2

Common Pitfall to Avoid

Do not delay cancer treatment unnecessarily. The endoscopy should be scheduled promptly, and if varices require treatment, bevacizumab can typically be started shortly after successful endoscopic intervention. The goal is risk mitigation, not indefinite treatment delay.